WebJan 9, 2024 · (Reuters) -AstraZeneca said on Monday it had struck a deal to buy U.S.-based drug developer CinCor Pharma Inc for up to $1.8 billion to increase its stock of heart and kidney drugs. Core to the deal is CinCor's experimental therapy baxdrostat, which is in development to treat conditions including high blood pressure and chronic kidney … WebJan 9, 2024 · CinCor stockholders holding approximately 44.8% of CinCor common stock have entered into a tender and support agreement with AstraZeneca, pursuant to which …
CinCor Hypertension Drug Flunks Study, But the Biotech Still Sees …
WebAug 8, 2024 · Conference Call and Webcast Information. CinCor management will hold a conference call and webcast today at 8:30 AM Eastern Time to provide an update on the BrigHtn Phase 2 trial. The dial-in ... WebYahoo February 21, 2024. CinCor CEO: acquisition by AstraZeneca was more than a year in the making. Before CinCor Pharma Inc. agreed to a $1.8 billion acquisition by AstraZeneca plc, it turned down several other offers from the U.K. pharmaceutical giant. Yahoo January 26, 2024. Why These Two Biotech Stocks Blasted Higher This Week thai consumer trend 2022
CinCor Pharma Announces Pricing of Upsized Public ... - Yahoo …
WebAug 8, 2024 · August 8, 2024, 5:34 PM · 5 min read. CinCor Pharma, Inc. WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical ... WebAug 8, 2024 · CinCor, founded in 2024, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases. WebFeb 24, 2024 · finance.yahoo.com - March 13 at 7:59 AM: CinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of Baxdrostat finance.yahoo.com - February 21 at 10:08 AM: As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' … symptom ruptured appendix